Enjaymo market forecast points to faster growth in Europe

The Business Research Company says the global Enjaymo market is being shaped by rising autoimmune disease diagnoses, more clinical trial activity and broader use of complement inhibitors. North America led the market in 2025, while Europe is projected to grow the fastest in the years ahead.

Why it matters: - Enjaymo is used for cold agglutinin disease, a rare autoimmune blood disorder with limited treatment options. - The market outlook signals where demand may rise for rare-disease biologics and complement inhibitors. - The report points to a broader expansion in specialty care, diagnostics and orphan-drug development.

What happened: - The Business Research Company published its Enjaymo Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report says North America was the dominant Enjaymo market in 2025. - The report forecasts Europe will be the fastest-growing regional market over the coming years. - The analysis covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample of the report is available. - A full version of the report is also available.

The details: - Enjaymo, or sutimlimab, is an approved complement inhibitor for adults with cold agglutinin disease. - The drug inhibits the C1s protein in the classical complement pathway. - That mechanism helps prevent red blood cell destruction and reduces the need for transfusions. - The report says historical growth came from limited treatment choices for CAD, higher diagnosis rates, successful use of complement inhibitors, more orphan-drug approvals and more specialty care centers. - Future growth is expected to come from a larger complement inhibitor pipeline, more awareness of rare hemolytic diseases, better diagnostic tools, supportive orphan-drug policies and broader adoption of specialty biologics. - Key trends highlighted in the report include therapies targeting the complement pathway, more treatment options for rare autoimmune diseases, precision immunology, fewer transfusion-dependent therapies and more orphan-drug development. - The report identifies growing autoimmune disorder prevalence as a main market driver. - The report cites a February 2024 Clinical Trials Arena projection that rheumatoid arthritis cases could rise 80.2% globally by 2050, affecting nearly 1% of the world population. - The report says rising clinical trial approvals are also supporting market growth. - The report cites an American Society of Gene and Cell Therapy update that 76 new gene therapy trials started in Q2 2024, up 25% from the prior quarter. - The report says the increase in clinical research can speed development and approval of drugs like Enjaymo.

Between the lines: - The market thesis depends less on Enjaymo as a standalone product and more on the broader ecosystem around rare autoimmune disease care. - Better diagnostics and faster trial activity can expand the addressable patient pool even without a dramatic change in the drug itself. - Europe’s growth outlook suggests commercial momentum may shift beyond the current North America lead.

What's next: - Watch for additional complement inhibitor launches and pipeline updates that could reshape competition. - Monitor regulatory and orphan-drug policy support, which could influence adoption in rare-disease markets. - The Business Research Company says its 2026 reports also add TAM analysis, company scoring matrices, forecasting dashboards, market hotspot infographics and updated trend graphics.